

Riccardo Scotto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2480081/publications.pdf>

Version: 2024-02-01

52
papers

943
citations

430442

18
h-index

500791

28
g-index

53
all docs

53
docs citations

53
times ranked

1702
citing authors

#	ARTICLE	IF	CITATIONS
1	Oral Vancomycin Prophylaxis for Primary and Secondary Prevention of Clostridioides difficile Infection in Patients Treated with Systemic Antibiotic Therapy: A Systematic Review, Meta-Analysis and Trial Sequential Analysis. <i>Antibiotics</i> , 2022, 11, 183.	1.5	16
2	Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study. <i>Journal of Neurology</i> , 2022, 269, 3301-3307.	1.8	9
3	SARS-CoV-2 in Kidney Transplant Patients: A Real-Life Experience. <i>Frontiers in Medicine</i> , 2022, 9, 864865.	1.2	8
4	Should SARS CoV-2 infection be considered an independent risk factor for Pneumocystis jirovecii pneumonia? Emerging data after two years of pandemic from a single center experience. <i>Reviews on Recent Clinical Trials</i> , 2022, 17, .	0.4	1
5	Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103814.	0.9	2
6	Epidemiological and clinical features of syphilis in the 21st century: A seven-year observational retrospective study of outpatients. <i>Clinical Epidemiology and Global Health</i> , 2022, 16, 101100.	0.9	3
7	Serum KL-6 Could Represent a Reliable Indicator of Unfavourable Outcome in Patients with COVID-19 Pneumonia. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2078.	1.2	24
8	Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitely Get a Role to Fusobacterium periodonticum?. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 625581.	1.8	59
9	<i>Pneumocystis jirovecii</i> pneumonia in an immunocompetent patient recovered from COVID-19. <i>Infectious Diseases</i> , 2021, 53, 382-385.	1.4	23
10	Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life "Liver Network Activity" (LINA) cohort update results. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1057-1063.	1.4	1
11	Chest CT in COVID-19 patients: Structured vs conventional reporting. <i>European Journal of Radiology</i> , 2021, 138, 109621.	1.2	10
12	Cytometric analysis of patients with COVID-19: what is changed in the second wave?. <i>Journal of Translational Medicine</i> , 2021, 19, 403.	1.8	5
13	<i>Pneumocystis jirovecii</i> Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11399.	1.2	24
14	Post-mortem diagnosis of invasive pulmonary aspergillosis after alemtuzumab treatment for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 123-126.	1.4	22
15	Direct-acting antivirals improve endothelial function in patients with chronic hepatitis: a prospective cohort study. <i>Internal and Emergency Medicine</i> , 2020, 15, 263-271.	1.0	23
16	Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 261-273.	0.9	8
17	Immunocytometric analysis of COVID patients: A contribution to personalized therapy?. <i>Life Sciences</i> , 2020, 261, 118355.	2.0	32
18	Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence. <i>Medicine (United States)</i> , 2020, 99, e18948.	0.4	6

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of ceftolozane/tazobactam as therapeutic option for complicated skin and soft tissue infections by MDR/XDR <i>Pseudomonas aeruginosa</i> in patients with impaired renal function: a case series from a single-center experience. <i>Infection</i> , 2020, 48, 303-307.	2.3	4
20	Novel strategies for the management of bacterial and fungal infections in patients with liver cirrhosis: focus on new antimicrobials. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 191-202.	2.0	3
21	The role of curcumin in liver diseases. <i>Archives of Medical Science</i> , 2019, 15, 1608-1620.	0.4	14
22	Interferon-free regimens improve kidney function in patients with chronic hepatitis C infection. <i>Journal of Nephrology</i> , 2019, 32, 763-773.	0.9	21
23	An update on recent developments in the search for hepatitis C virus therapies with pan-genotypic efficacy. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 395-397.	1.9	4
24	Incidence and Predictive Risk Factors of Infective Events in Patients With Multiple Sclerosis Treated With Agents Targeting CD20 and CD52 Surface Antigens. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz445.	0.4	21
25	Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity "LINA). <i>Tijdschrift voor Gastroenterologie</i> , 2019, 14, 107-114.	0.784314	10
26	Severe Vitamin D Deficiency Increases Mortality Among Patients With Liver Cirrhosis Regardless of the Presence of HCC. <i>In Vivo</i> , 2019, 33, 177-182.	0.6	16
27	The serum-ascites vitamin D gradient (SADG): A novel index in spontaneous bacterial peritonitis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2019, 43, e57-e60.	0.7	6
28	Unsolved Issues in the Treatment of Spontaneous Peritonitis in Patients with Cirrhosis: Nosocomial Versus Community-acquired Infections and the Role of Fungi. <i>Reviews on Recent Clinical Trials</i> , 2019, 14, 129-135.	0.4	6
29	Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection. <i>Reviews on Recent Clinical Trials</i> , 2019, 14, 173-182.	0.4	30
30	Hepatitis C screening in the Emergency Department of a large hospital in southern Italy: results of a pilot study. <i>Infezioni in Medicina</i> , 2019, 27, 32-39.	0.7	4
31	Efficacy of the "first wave" Direct Acting antivirals against HCV infection: results from the Italian LINA (Liver Network Activity) cohort. <i>New Microbiologica</i> , 2019, 42, 94-100.	0.1	5
32	Lack of efficacy of <i>Lactobacillus GG</i> in reducing pulmonary exacerbations and hospital admissions in children with cystic fibrosis: A randomised placebo controlled trial. <i>Journal of Cystic Fibrosis</i> , 2018, 17, 375-382.	0.3	28
33	Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 709-717.	1.0	55
34	Prevalence and risk factors of erectile dysfunction in patients with hepatitis B virus or hepatitis C virus or chronic liver disease: results from a prospective study. <i>Sexual Health</i> , 2018, 15, 408.	0.4	16
35	Does compulsory vaccination limit personal freedom? Ethical issues. <i>Australasian Medical Journal</i> , 2018, 11, .	0.1	0
36	Epidemiology and risk factors for hepatitis C virus genotypes in a high prevalence region in Italy. <i>New Microbiologica</i> , 2018, 41, 26-29.	0.1	18

#	ARTICLE	IF	CITATIONS
37	Infections worsen prognosis of patients with cirrhosis irrespective of the liver disease stage. <i>European Journal of Internal Medicine</i> , 2017, 46, e45-e47.	1.0	16
38	Vitamin D deficiency is a risk factor for infections in patients affected by HCV-related liver cirrhosis. <i>International Journal of Infectious Diseases</i> , 2017, 63, 23-29.	1.5	26
39	Successful treatment of post-surgical osteomyelitis caused by XDR <i>Pseudomonas aeruginosa</i> with ceftolozane/tazobactam monotherapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2678-2679.	1.3	16
40	Diagnostic Accuracy of PIVKA-II, Alpha-Fetoprotein and a Combination of both in Diagnosis of Hepatocellular Carcinoma in Patients Affected by Chronic HCV Infection. <i>In Vivo</i> , 2017, 31, 695-700.	0.6	15
41	Factors Affecting Outcome of Tuberculosis in Children in Italy: An Ecological Study. <i>Advances in Experimental Medicine and Biology</i> , 2016, 973, 71-79.	0.8	1
42	The therapeutic potential of new investigational hepatitis C virus translation inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1209-1214.	1.9	14
43	Recommendations for pediatric tuberculosis vaccination in Italy. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 644-650.	1.4	2
44	Recommendations Concerning the First-Line Treatment of Children with Tuberculosis. <i>Paediatric Drugs</i> , 2016, 18, 13-23.	1.3	11
45	Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 557-572.	1.9	19
46	Indications to Hospital Admission and Isolation of Children With Possible or Defined Tuberculosis. <i>Medicine (United States)</i> , 2015, 94, e2045.	0.4	8
47	The impact of <i>Clostridium difficile</i> infection on resource use and costs in hospitals in Spain and Italy: a matched cohort study. <i>International Journal of Infectious Diseases</i> , 2015, 36, 31-38.	1.5	23
48	Asunaprevir for hepatitis C: a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1631-1646.	1.0	6
49	How to manage children who have come into contact with patients affected by tuberculosis. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2015, 1, 1-12.	0.6	9
50	Disrupted Intestinal Microbiota and Intestinal Inflammation in Children with Cystic Fibrosis and Its Restoration with <i>Lactobacillus GG</i> : A Randomised Clinical Trial. <i>PLoS ONE</i> , 2014, 9, e87796.	1.1	182
51	Adherence to Guidelines for Management of Children Hospitalized for Acute Diarrhea. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 1103-1108.	1.1	20
52	Monoclonal antibodies against <i>Clostridium difficile</i> infection in the pipeline. <i>Drugs of the Future</i> , 2014, 39, 693.	0.0	2